ATE552500T1 - Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität - Google Patents

Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Info

Publication number
ATE552500T1
ATE552500T1 AT10164461T AT10164461T ATE552500T1 AT E552500 T1 ATE552500 T1 AT E552500T1 AT 10164461 T AT10164461 T AT 10164461T AT 10164461 T AT10164461 T AT 10164461T AT E552500 T1 ATE552500 T1 AT E552500T1
Authority
AT
Austria
Prior art keywords
clostridial toxin
clostridial
toxinactivity
lipophilic
dye
Prior art date
Application number
AT10164461T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Lance E Steward
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE552500T1 publication Critical patent/ATE552500T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Glass Compositions (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT10164461T 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität ATE552500T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66894205P 2005-04-05 2005-04-05

Publications (1)

Publication Number Publication Date
ATE552500T1 true ATE552500T1 (de) 2012-04-15

Family

ID=36975328

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06749210T ATE470857T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
AT10164461T ATE552500T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06749210T ATE470857T1 (de) 2005-04-05 2006-04-04 Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Country Status (10)

Country Link
US (2) US8124357B2 (de)
EP (2) EP1869459B1 (de)
AT (2) ATE470857T1 (de)
AU (1) AU2006231470B2 (de)
CA (1) CA2604039C (de)
DE (1) DE602006014812D1 (de)
DK (1) DK1869459T3 (de)
ES (1) ES2345506T3 (de)
PT (1) PT1869459E (de)
WO (1) WO2006107921A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
ATE533853T1 (de) * 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
ATE470857T1 (de) * 2005-04-05 2010-06-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
JP2009521666A (ja) * 2005-10-12 2009-06-04 アラーガン、インコーポレイテッド 共鳴エネルギー移動後の偏光解消（ｄａｒｅｔ）を用いる分子または細胞より小さい部分の相互作用力のアッセイ
WO2008140834A2 (en) 2007-01-16 2008-11-20 The Regents Of The University Of California Novel antimicrobial peptides
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
LT3031825T (lt) * 2008-03-14 2020-02-10 Allergan, Inc. Botulino toksino serotipo a aktyvumo imuninio tyrimo būdai
EP2406629B9 (de) 2009-03-13 2014-03-26 Allergan, Inc. Immunbasierte testverfahren für endopeptidase-aktivität mit neuem ziel
WO2010105234A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Cells useful for immuno-based botulinum toxin serotype a activity assays
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US10246492B2 (en) 2009-10-16 2019-04-02 Biomadison, Inc. Botulinum assay with synaptobrevin substrate moiety
EP2488868B1 (de) * 2009-10-16 2016-03-30 BioMadison, Inc. Resonanzenergie-transferassay mit einem synaptobrevin-fragment als substrat
KR20130111954A (ko) * 2010-06-11 2013-10-11 시냅틱 리서치, 엘엘씨 N-단부 지배 프로테아제 활성 표시 방법 및 이의 용도
EP2788478B1 (de) * 2011-12-09 2017-08-23 Institut Pasteur Multiplex-immunoscreening-test
US10451621B2 (en) 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
US8778623B2 (en) * 2012-09-14 2014-07-15 Wisconsin Alumni Research Foundation Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin
US8962340B2 (en) 2012-12-03 2015-02-24 Src, Inc. Real-time assay for the detection of botulinum toxin
DE102013226537B4 (de) 2013-12-18 2022-12-29 TRUMPF Hüttinger GmbH + Co. KG Leistungsversorgungssystem mit mehreren Verstärkerpfaden sowie Verfahren zur Anregung eines Plasmas
DE102013226511B4 (de) 2013-12-18 2016-12-15 TRUMPF Hüttinger GmbH + Co. KG Leistungsversorgungssystem und Verfahren zur Erzeugung einer Leistung
EP3567055A1 (de) 2014-07-07 2019-11-13 Allergan, Inc. Verfahren zum nachweis von gespaltenem snap25 in gewebeproben
US9788776B1 (en) 2014-09-22 2017-10-17 Verily Life Sciences Llc Protein M-based in vivo diagnostic system and detection method
US9927442B1 (en) 2014-10-31 2018-03-27 Verily Life Sciences Llc Biosensor for in vitro detection system and method of use
CA2971271C (en) 2014-12-19 2022-09-06 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of bont/e in cells
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3458600A4 (de) 2016-05-16 2020-01-15 BioMadison, Inc. Verbesserter test mit teil auf der basis von synaptobrevin
WO2018053004A2 (en) 2016-09-13 2018-03-22 Allergan, Inc. Non-protein clostridial toxin compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2020123346A (ru) 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для лечения расстройств, связанных с фиброзом
TW202113072A (zh) * 2019-06-07 2021-04-01 美商辛那皮克研究有限責任公司 基因工程化細胞
EP4014039A1 (de) * 2019-08-13 2022-06-22 Synaptic Research, LLC Für clostridienneurotoxin hochempfindliche zellen
CN110840914B (zh) * 2019-11-23 2021-07-06 博雅干细胞科技有限公司 细胞治疗剂用于缓解或改善血管病变的方法
CN110882276B (zh) * 2019-11-23 2021-07-06 博雅干细胞科技有限公司 细胞治疗组合物及治疗血管病变的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965699A (en) 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
FR2809733B1 (fr) 2000-06-02 2004-04-30 Inst Nat Sante Rech Med Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants
EP1419390B1 (de) 2000-09-25 2007-11-14 U.S. Medical Research Institute of Infectious Diseases Hoch-durchsatz assays für proteolytische aktivitäten von clostridium neurotoxinen
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20060063221A1 (en) 2004-09-21 2006-03-23 Williams Dudley J Lanthanide-based substrates and methods for determining clostridial toxin activity
WO2004020748A1 (en) 2002-08-28 2004-03-11 Btb Wallercode Sdn Bhd Rainwater collection, storage and supply system
AU2003279020A1 (en) 2002-09-26 2004-04-19 Rensselaer Polytechnic Institute Analytical instruments for monitoring photopolymerization
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
WO2004031355A2 (en) 2002-10-01 2004-04-15 University Of Maryland Methods for identifying inhibitors of botulinum neurotoxins
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP2502930B1 (de) 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Verfahren und zusammensetzungen zum nachweis von botulinum-neurotoxin
ATE380880T1 (de) 2004-05-05 2007-12-15 Pharmaleads Mittels botulinumtoxin a (bont/a) erkennbare peptidsubstrate und verwendung
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
ATE470857T1 (de) * 2005-04-05 2010-06-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität

Also Published As

Publication number Publication date
US8535941B2 (en) 2013-09-17
US20120231538A1 (en) 2012-09-13
US8124357B2 (en) 2012-02-28
WO2006107921A3 (en) 2007-01-18
EP1869459A2 (de) 2007-12-26
EP2293064B1 (de) 2012-04-04
ATE470857T1 (de) 2010-06-15
DK1869459T3 (da) 2010-09-27
CA2604039C (en) 2014-09-16
ES2345506T3 (es) 2010-09-24
DE602006014812D1 (de) 2010-07-22
AU2006231470B2 (en) 2011-12-01
AU2006231470A1 (en) 2006-10-12
US20080160561A1 (en) 2008-07-03
WO2006107921A2 (en) 2006-10-12
CA2604039A1 (en) 2006-10-12
PT1869459E (pt) 2010-08-10
EP1869459B1 (de) 2010-06-09
EP2293064A1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
ATE470857T1 (de) Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
NO20051049D0 (no) Celle-baserte fluorescens-resonans energi overforings (FRET)-analyser for Clostridietoksiner
ATE528648T1 (de) Verfahren zum nachweis antikörper-herstellender zellen
WO2009058902A3 (en) Methods and devices for analyte detection
WO2005047863A3 (en) Substrates, devices, and methods for cellular assays
ATE527383T1 (de) Multiplex-nukleinsäurenachweis
DE602006018477D1 (de) Dna und antikörpern sowie verwendungen davon
DK2073008T3 (da) Forbedrede immunoassayfremgangsmåder
WO2007103859A3 (en) Methods, products, and kits for identifying an analyte in a sample
WO2006071247A3 (en) Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots
AU4701200A (en) A method of detecting an analyte using semiconductor nanocrystals
WO2006121799A3 (en) Liquid crystal based analyte detection
EP2093565A3 (de) Substrate, Vorrichtungen und Verfahren für zelluläre Assays
WO2008066584A3 (en) Rapid analyte measurement assay
DK1920248T3 (da) Clostridialt-toksin-aktivitetsassays
AU2003224447A1 (en) Device and method to simultaneously detect different antibodies and antigens in clinical alimentary and environmental samples
ATE532830T1 (de) Langwellige thiolgruppenreaktive fluorophore
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
WO2011142781A3 (en) Pore-limit electrophoresis (ple) microchannel assays
WO2007133496A3 (en) Development of a novel assay for mgmt (methyl guanine transferase)
DE60331686D1 (de) Mikroarray-vorrichtungen mit steuerbarem reaktionsvolumen
ATE371747T1 (de) Dendritische chemilumineszierende substrate
WO2009017234A1 (ja) γ-セクレターゼの新規基質c-Retを利用したスクリーニング方法
WO2009126889A8 (en) Assays for detecting pregnancy-associated glycoproteins
ATE529749T1 (de) Chromatographische teststreifen für ein oder mehrere analyte